#1

Monday, May 13, 2024

8:00 am PT, 11:00 am ET, 17:00 CET

REGISTER FREE

With approvals of novel cell and gene therapy products by the FDA anticipated to reach double figures in 2024 – following eight US approvals in 2023 – advancements in cell and gene therapy (CGT) products are paving the way for early-stage program developers. Now more than ever, it is critical to consider the end-product from the very beginning, establishing a scalable and robust process, and identifying opportunities to streamline without compromising on quality.

WIn this roundtable webinar, our expert panelists from across the CGT space will discuss a concept-to-cure program pathway, sharing insights and exploring challenges from a development, manufacturing, and testing perspective. Among the key audience takeaways will be:

  • Key differences between material requirements for research vs. GMP vectors
  • The importance of standardizing materials and manufacturing processes
  • Real-world examples of how the pathway to the clinic can be streamlined

See link;

https://gen.omeclk.com/portal/public/ViewCommInBrowser.jsp?2I8xi3TTdj9NG4oU8Aa8yO84wW%2BRGbaqrHDk5lUCqijw5XeYaqeVrPFq%2FCXRv14Ob2YVEgrmAhEnSXti%2FEUMCQ%3D%3DA